Randomized Controlled Trial of Lymphoblastoid Interferon-α for Chronic Hepatitis C; Early Disappearance of HCV RNA is Essential for Sustained Response

  • Shinichi Kakumu
  • IFN Treatment Group of Affiliated Hospitals of the Third Department of Internal Medicine
Conference paper


Interferon (IFN) therapy has been shown to be efficacious in some patients with chronic hepatitis C [1–4]. In responders, normal alanine aminotransferase (ALT) levels and disappearance of hepatitis C virus (HCV) from serum continues for several years and probably permanently after IFN. Such a response is called sustained response, and has been thought to benefit the prognosis of the patients.


Chronic Hepatitis Sustained Response Million Unit Sustained Response Rate Sustained Responder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Davis GL, Baklart LA, Schiff ER, et al (1989) Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N Engl J Med 321:1501–1506PubMedCrossRefGoogle Scholar
  2. 2.
    Di Bisceglie AM, Martin P, Kassianides C, et al (1989) Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506–1510PubMedCrossRefGoogle Scholar
  3. 3.
    Marcellin P, Boyer N, Giostra E, et al (1991) Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 13:393–397PubMedCrossRefGoogle Scholar
  4. 4.
    Pagliaro L, Craxi A, Cammaa C, et al (1994) Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 19:820–828PubMedGoogle Scholar
  5. 5.
    Chemello L, Bonetti P, Cavalletto L, et al (1995) Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 22:700–706PubMedGoogle Scholar
  6. 6.
    Shiratori Y, Kato N, Yokosuka O, et al (1997) Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 113:558–566PubMedCrossRefGoogle Scholar
  7. 7.
    Desmet VJ, Gerber M, Hoofnagle JH, et al (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513–1520PubMedCrossRefGoogle Scholar
  8. 8.
    Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, et al (1994) Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 19:1347–1353PubMedCrossRefGoogle Scholar
  9. 9.
    Simmonds P, McOmish F, Yap PL, et al (1993) Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 74:661–668PubMedCrossRefGoogle Scholar
  10. 10.
    Urdea MS, Horn T, Fultz TJ, et al (1991) Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Symp Ser 24:197–200PubMedGoogle Scholar
  11. 11.
    Lau JYN, Davis GL, Kniffen J, et al (1993) Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341:1501–1504PubMedCrossRefGoogle Scholar
  12. 12.
    Yoshioka K, Higashi Y, Yamada M, et al (1995) Predictive factors in the response to interferon therapy in chronic hepatitis C. Liver 15:57–62PubMedGoogle Scholar
  13. 13.
    Yoshioka K, Kakumu S, Wakita T, et al (1992) Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 16:293–299PubMedCrossRefGoogle Scholar
  14. 14.
    Hino K, Okuda M, Konishi T, et al (1995) Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy. Dig Dis Sci 40:14–20PubMedCrossRefGoogle Scholar
  15. 15.
    Orito E, Mizokami M, Suzuki K, et al (1995) Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 46:109–115PubMedCrossRefGoogle Scholar
  16. 16.
    Kakumu S, Aiyama T, Okumura A, et al (1997) Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. J Gastroenterol Hepatol 12:468–472PubMedCrossRefGoogle Scholar
  17. 17.
    Sharara AI, Hunt CM, Hamilton JD (1996) Hepatitis C. Ann Intern Med 125:658–668PubMedGoogle Scholar
  18. 18.
    Kakumu S, Yoshioka K, Tanaka K, et al (1993) Long-term carrier state of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C. J Med Virol 41:65–70PubMedCrossRefGoogle Scholar
  19. 19.
    Lau JY, Mizokami M, Ohno T, et al (1993) Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet 342:1208–1209PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1999

Authors and Affiliations

  • Shinichi Kakumu
    • 1
  • IFN Treatment Group of Affiliated Hospitals of the Third Department of Internal Medicine
    • 2
  1. 1.First Department of Internal MedicineAichi Medical UniversityNagakute-cho, Aichi-gun, AichiJapan
  2. 2.Nagoya University School of MedicineJapan

Personalised recommendations